IL314331A - Methods and compounds for reducing oxidation of IGF-1/IGFBP - Google Patents

Methods and compounds for reducing oxidation of IGF-1/IGFBP

Info

Publication number
IL314331A
IL314331A IL314331A IL31433124A IL314331A IL 314331 A IL314331 A IL 314331A IL 314331 A IL314331 A IL 314331A IL 31433124 A IL31433124 A IL 31433124A IL 314331 A IL314331 A IL 314331A
Authority
IL
Israel
Prior art keywords
formulation
igf
composition
polysorbate
igfbp
Prior art date
Application number
IL314331A
Other languages
English (en)
Hebrew (he)
Inventor
Nazila Salamat-Miller
Kris Lowe
Michael Hahn
Katherine Taylor
Original Assignee
Oak Hill Bio Ltd
Salamat Miller Nazila
Kris Lowe
Michael Hahn
Katherine Taylor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oak Hill Bio Ltd, Salamat Miller Nazila, Kris Lowe, Michael Hahn, Katherine Taylor filed Critical Oak Hill Bio Ltd
Publication of IL314331A publication Critical patent/IL314331A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
IL314331A 2022-01-19 2023-01-18 Methods and compounds for reducing oxidation of IGF-1/IGFBP IL314331A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263300860P 2022-01-19 2022-01-19
PCT/EP2023/051110 WO2023139115A1 (en) 2022-01-19 2023-01-18 Compositions and methods for reducing oxidation of igf‐1/igfbp

Publications (1)

Publication Number Publication Date
IL314331A true IL314331A (en) 2024-09-01

Family

ID=85036292

Family Applications (1)

Application Number Title Priority Date Filing Date
IL314331A IL314331A (en) 2022-01-19 2023-01-18 Methods and compounds for reducing oxidation of IGF-1/IGFBP

Country Status (10)

Country Link
US (1) US20250099541A1 (cg-RX-API-DMAC10.html)
EP (1) EP4466281A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025502349A (cg-RX-API-DMAC10.html)
KR (1) KR20240136382A (cg-RX-API-DMAC10.html)
CN (1) CN118574840A (cg-RX-API-DMAC10.html)
AU (1) AU2023210427A1 (cg-RX-API-DMAC10.html)
CA (1) CA3242513A1 (cg-RX-API-DMAC10.html)
IL (1) IL314331A (cg-RX-API-DMAC10.html)
MX (1) MX2024008819A (cg-RX-API-DMAC10.html)
WO (1) WO2023139115A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230113287A (ko) * 2020-10-19 2023-07-28 오크 힐 바이오 리미티드 신생아에 사용하기에 적합한 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
ATE90690T1 (de) 1987-04-06 1993-07-15 Celtrix Pharma Menschliche somatomedin-traeger-proteinuntereinheiten und verfahren zu ihrer herstellung.
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
ATE132164T1 (de) 1988-04-12 1996-01-15 Amgen Boulder Inc Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
EP0639981A4 (en) 1992-05-08 1995-06-28 Univ Jefferson ANALOGS OF THE IGF FACTOR (01/18/94).
US5563046A (en) 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US5789547A (en) 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
KR20230113287A (ko) 2020-10-19 2023-07-28 오크 힐 바이오 리미티드 신생아에 사용하기에 적합한 조성물

Also Published As

Publication number Publication date
AU2023210427A2 (en) 2025-01-09
CN118574840A (zh) 2024-08-30
KR20240136382A (ko) 2024-09-13
CA3242513A1 (en) 2023-07-27
EP4466281A1 (en) 2024-11-27
WO2023139115A1 (en) 2023-07-27
JP2025502349A (ja) 2025-01-24
US20250099541A1 (en) 2025-03-27
AU2023210427A1 (en) 2024-08-22
MX2024008819A (es) 2024-09-17

Similar Documents

Publication Publication Date Title
JP5753692B2 (ja) タンパク質製剤
US6174856B1 (en) Stabilized insulin compositions
US6013773A (en) Pharmaceutical preparation containing human growth hormone
WO2000051629A1 (en) Preparations stabilized over long time
CA2275890A1 (en) Stable liquid interferon formulations
JPWO2000051629A1 (ja) 長期安定化製剤
WO2001064241A1 (en) Preparations stabilized over long time
EP1599222A1 (en) Stabilized aqueous compositions comprising tissue factor pathway inhibitor (tfpi) or tissue factor pathway inhibitor variant
CZ20011134A3 (cs) Stabilní koncentrované insulinové přípravky pro plicní podávání
FI4228676T3 (fi) Koostumuksia, jotka sopivat vastasyntyneillä käytettäviksi
EP0284249A1 (en) Lyophilized lymphokine composition
CA3054788A1 (en) Stabilized external use agent comprising thymosin beta-4 as effective ingredient
JPWO1999044630A1 (ja) 蛋白非添加製剤
JP2025502349A5 (cg-RX-API-DMAC10.html)
EP2473194A1 (en) Stable formulation of factor viii
EP1231933A1 (en) An aqueous solution formulation of alpha-interferon
RU2024122721A (ru) Композиции и способы для уменьшения окисления igf-1/igfbp
JP2025502349A (ja) Ｉｇｆ－１／ｉｇｆｂｐの酸化を低減するための組成物および方法
JP4610154B2 (ja) 注射用製剤
JP2017528526A (ja) α型インターフェロンを含有する安定したベンジルアルコールフリーの水溶液製剤
WO2023066988A1 (en) Glass container with low aluminum content and gas overlay to prevent oxidation of sensitive therapeutic agents
JP2015224219A (ja) 凍結乾燥製剤
EP2399572A1 (en) Long-term storage of non-glycosylated recombinant human G-CSF
WO2007034509A2 (en) Recombinant granulocyte-colony stimulating factor formulation and process
JP2024518178A5 (cg-RX-API-DMAC10.html)